Health Care • Biotechnology: Pharmaceutical Preparations
$1.18 ▼ -0.04
(-3.28%)
MKT CAP: $2.6M • VOL: 33.4K
52W L $1 52W H $24
ROARABLE / RQD
E • 27/100
PIOTROSKI
1 / 9
HCWB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $54.2K | $2.6M | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $10.8K | $959.4K | — |
| Gross Margin % | 20.0% | 37.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$13.2M | -$29.5M | -$25.7M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$8.0M | -$30.0M | -$25.0M |
| EBITDA (Normalized) | -$13.2M | -$29.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$13.4M | -$14.2M | -$22.5M |
| Capital Expenditures (CapEx) | $0 | $261.6K | — |
| Free Cash Flow (FCF) | -$13.4M | -$14.5M | -$22.5M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $2.0M | $4.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $2.8M | -$6.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR HCWB.